Cetera Investment Advisers
TSHA icon

Cetera Investment Advisers’s Taysha Gene Therapies TSHA Stock Holding History

Cetera Investment Advisers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
31,607
+3,157
+11% +$18.7K ﹤0.01% 4439
2026
Q1 		$127K Buy
28,450
+7,296
+34% +$33.9K ﹤0.01% 4398
2025
Q4 		$116K Buy
21,154
+4,992
+31% +$24.2K ﹤0.01% 4363
2025
Q3 		$52.9K Buy
+16,162
New +$45.8K ﹤0.01% 4423

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cetera Investment Advisers's TSHA Position: Q2 2026 in Review

Cetera Investment Advisers increased its Taysha Gene Therapies (TSHA) stake by 11% in Q2 2026, buying an estimated $18.7K and bringing the position to 31,607 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #4439.

Cetera Investment Advisers first reported a position in TSHA in Q3 2025 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Cetera Investment Advisers held 31,607 shares of Taysha Gene Therapies worth $215K as of Q2 2026.
  • Cetera Investment Advisers bought 3,157 Taysha Gene Therapies shares in Q2 2026, an estimated $18.7K.
  • Taysha Gene Therapies made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4439 holding.
  • Cetera Investment Advisers first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.